Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the science is hard enough—decoding the disclosures behind it can feel impossible. Syndax Pharmaceuticals’ 10-K often buries trial outcomes for revumenib and axatilimab deep inside 200-plus pages, while surprise 8-K updates surface new royalty deals overnight. If you have ever asked, “Where can I find the Syndax Pharmaceuticals quarterly earnings report 10-Q filing?” or searched for “Syndax Pharmaceuticals insider trading Form 4 transactions,” you already know the challenge.
Stock Titan turns that problem into a two-minute read. Our AI-powered summaries translate technical oncology language into plain English, flagging the exact tables that spell out cash runway, R&D spend, and upcoming FDA milestones. Need the “Syndax Pharmaceuticals annual report 10-K simplified” or a quick “Syndax Pharmaceuticals earnings report filing analysis”? Get both, side-by-side with management commentary, without sifting through footnotes. Real-time alerts push every “Syndax Pharmaceuticals Form 4 insider transactions real-time,” so you can monitor executive stock transactions before the market reacts. We also map each “Syndax Pharmaceuticals proxy statement executive compensation” item to performance targets and surface every “Syndax Pharmaceuticals 8-K material events explained” entry within minutes of hitting EDGAR.
From pipeline-critical 10-Q updates to sudden 8-K clinical data releases, every filing is cataloged, timestamped, and linked to context. Investors use our platform to compare quarter-over-quarter R&D trends, track insider buying patterns, and understand collaboration economics—without drowning in jargon. Start understanding Syndax Pharmaceuticals SEC documents with AI and make faster, evidence-based decisions.
Syndax Pharmaceuticals (Nasdaq:SNDX) filed an 8-K under Item 5.02 reporting the resignation of director William Meury, effective June 24 2025. Meury stepped down to become President, CEO and board member of Incyte Corporation, Syndax’s collaboration partner on Niktimvo™ (axatilimab-csfr). The company states the departure involves no disagreements regarding its operations, policies or practices. No successor or board-composition changes were disclosed.
While day-to-day operations and partnership terms remain unchanged, investors should watch for follow-up filings detailing any replacement director or shifts in oversight of the Incyte collaboration.
FAQ
What is the current stock price of Syndax Pharmaceuticals (SNDX)?
What is the market cap of Syndax Pharmaceuticals (SNDX)?
What is Syndax Pharmaceuticals Inc?
What are the company’s primary product candidates?
How does revumenib work?
What distinguishes axatilimab in treatment?
How does Syndax generate revenue?
What role do clinical trials play in their strategy?
How does Syndax ensure scientific expertise and trustworthiness?
What makes Syndax unique in a competitive market?
